 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Vical Incorporated
 |
Vical Incorporated |
 |
 |
 |
PROFILE |
 |
Vical isn't about to cover up its naked DNA. The firm develops gene-based treatments and preventions for cancer, infectious diseases, and metabolic disorders in humans and animals. These treatments rely on "naked DNA," or DNA that does not have to be loaded into a viral body to be introduced into targeted cells. With such development partners as Merck, Pfizer, Human Genome Sciences, and units of Aventis, Vical is working on Leuvectin, which stimulates an immune response against kidney and prostate cancer; Vaxid, a vaccine against relapsing B-cell lymphoma; Allovectin-7, another therapy to stimulate an immune response against metastic melanoma and head and neck cancer; and other drug candidates.
COMPETITION |
 |
TRANSGENE S.A. (TRGNY)
Targeted Genetics Corporation (TGEN)
Valentis, Inc. (VLTS)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 7.60
1-Yr. Sales Growth: (29.0)%
Employees: 134
Revenue per employee: $56,716.42
KEY PEOPLE |
 |
Vijay B. Samant
CEO
Martha J. Demski
CFO
CONTACT INFO |
 |
9373 Towne Centre Dr., Ste. 100
San Diego, CA 92121
US
Phone: 858-646-1100
Fax: 858-646-1150
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |